<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"
  dtd-version="1.3" xml:lang="en" article-type="research-article">
  <?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
  <?SourceDTD.Version 1.2?>
  <?ConverterInfo.XSLTName jats2jats3.xsl?>
  <?ConverterInfo.Version 1?>
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="iso-abbrev">Pharmacophore</journal-id>
      <journal-id journal-id-type="publisher-id">pharmacophorejournal.com</journal-id>
      <journal-id journal-id-type="publisher-id">Pharmacophore</journal-id>
      <journal-title-group>
        <journal-title>Pharmacophore</journal-title>
      </journal-title-group>
      <issn pub-type="epub">2229-5402</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">pharmacophorejournal.com-6799</article-id>
      <article-id pub-id-type="doi">10.51847/fe28C95Ygw</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Oncogenic Potential of Persistent Infection with Human Papillomavirus</article-title>
      </title-group>
                    <contrib-group>
                      <contrib contrib-type="author">
              <name>
                <surname>Nica-Badea</surname>
                <given-names>Delia</given-names>
              </name>
                              <xref rid="aff1" ref-type="aff">1</xref>
                                        </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Mihaela</surname>
                <given-names>Vladu Ionela</given-names>
              </name>
                              <xref rid="aff2" ref-type="aff">2</xref>
                                                            <xref rid="cor1" ref-type="corresp" />
                          </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Răzvan</surname>
                <given-names>Mogoș Gabriel Florin</given-names>
              </name>
                              <xref rid="aff3" ref-type="aff">3</xref>
                                        </contrib>
                      <contrib contrib-type="author">
              <name>
                <surname>Stefanita</surname>
                <given-names>Tenea Cojan Tiberiu</given-names>
              </name>
                              <xref rid="aff4" ref-type="aff">4</xref>
                                        </contrib>
                  </contrib-group>
                  <aff id="aff1">
            <label>1</label>Faculty of Medical Science and Behaviours, Constantin Brancusi University, Targu-Jiu, Romania
          </aff>
                  <aff id="aff2">
            <label>2</label>Department of Diabetes, Nutrition and Metabolic Diseases, University of Medicine and Pharmacy Craiova, Romania.
          </aff>
                  <aff id="aff3">
            <label>3</label>Department of Obstetrics-Gynecology, University of Medicine and Pharmacy Craiova, Romania.
          </aff>
                  <aff id="aff4">
            <label>4</label>Department of Surgery, University of Medicine and Pharmacy Craiova, Romania.
          </aff>
                          <author-notes>
            <corresp id="cor1">
              <bold>Address for correspondence:</bold> Prof. Wael Abu Dayyih, Department of
              Pharmaceutical Chemistry, Faculty of Pharmacy, Mutah University, Al-Karak 61710, Jordan.
                              E-mail: <email xlink:href="ionela.vladu@umfcv.ro">ionela.vladu@umfcv.ro</email>
                          </corresp>
          </author-notes>
                    <pub-date pub-type="epub">
        <day>13</day>
        <month>04</month>
        <year>2024</year>
      </pub-date>
      <volume>15</volume>
      <issue>1</issue>
      <fpage>57</fpage>
      <lpage>64</lpage>
      <permissions>
        <copyright-statement>
          Copyright: &#x000a9; 2026 Pharmacophore
        </copyright-statement>
        <copyright-year>2026</copyright-year>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
            specific-use="textmining" content-type="ccbyncsalicense">
            https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref>
          <license-p>This is an open access journal, and articles are distributed under the terms of
            the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows
            others to remix, tweak, and build upon the work non-commercially, as long as appropriate
            credit is given and the new creations are licensed under the identical terms.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>A<sc>BSTRACT</sc></title>
        <p>Given that they are a group of small-chain DNA viruses, certain human papillomaviruses (HPVs) may either produce benign sickness or be found in human cancerous tumors.  Oncogenic risk strains - as evidenced by the literature - infect epithelial cells so they are detected in the skin and in the mucous membranes (genital, anal, oral and respiratory). The primary risk factor for the formation of many malignant tumors in humans is ongoing human papillomavirus infection, which can occur in many anatomical locations. The most studied are HPV16 and HPV18, because they have the highest carcinogenic activity, while onco-E6 and E7 participate in cell transformation and carcinogenesis induced by HPV, because they are essential factors for immortalization. The current literature is presented in this review which is a critical and comprehensive summary focusing on: the structure and organization of the HPV genome, the cycle of viral infection, focusing on the functional importance of the HPV oncoproteins, E6 and E7, which drive atypical cell proliferation, abnormal, diagnosing precancerous diseases, but also determining the condition, their prevention and the necessary therapy for this type of HPV infection.</p>
      </abstract>
      <kwd-group>
              </kwd-group>
    </article-meta>
  </front>
</article>